Zynerba Pharma (ZYNE) Presents Positive Data from Phase 2 INSPIRE Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
14.11.2022 - Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 $55.9 million in cash and cash equivalents at September 30, 2022; Cash runway into .
Zynerba Pharma (ZYNE) Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Let’s start up with the current stock price of Zynerba Pharmaceuticals Inc. (ZYNE), which is $1.12 to be very precise. The Stock rose vividly during the last session to $1.16 after opening rate of $1.15 while the lowest price it went was recorded $1.0813 before closing at $1.16.Recently in News on